Arvinas Inc (ARVN) Stock Price, Quote & News

Company Profile

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs , including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein fo...

Industry: Biotechnology

Sector: Healthcare

Phone: 203 535 1456

Website: www.arvinas.com

Address:

5 Science Park, 395 Winchester Avenue, New Haven, United States

Greatguns Mar. 19 at 10:49 PM

$ARVN Arvinas (NASDAQ:ARVN) Price Target Raised to $21.00 at Citigroup

0 · Reply

erevnon Mar. 19 at 1:23 PM

BTIG maintains Arvinas $ARVN at Buy and raises the price target from $14 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

BioSpecialOne Mar. 18 at 2:00 PM

$ARVN The drop to 11.06 is a textbook retail shakeout and stop loss hunting after breaking the 11.50 technical support. Retail traders bought the rumor hoping for a massive buyout announcement at Copenhagen and panic sold when they only got excellent Phase 1 safety and efficacy data. But look at the options flow. The smart money is not panicking. The Put to Call ratio is around 0.3 meaning institutions are holding their long positions. The heavy volume is still sitting on the 15 and 20 dollar strike calls targeting the June 5 breast cancer PDUFA. Institutions know this company has 685 million dollars in cash providing a runway to 2028 so there is zero immediate dilution risk. Director Briggs Morrison did not drop his own money on 20000 shares at 13.40 just to day trade a Phase 1 update. He positioned himself for June. The underlying science is validated and the clinical execution is flawless. Do not let algorithms steal your shares in a low volume technical flush.

2 · Reply

BioSpecialOne Mar. 18 at 12:09 PM

$ARVN Excellent execution on the Phase 1 ARV 102 Parkinson data. Achieving over 50 percent LRRK2 degradation in the CSF with zero serious adverse events is a massive validation of their PROTAC platform successfully crossing the blood brain barrier. Now the market knows exactly why Director Briggs Morrison loaded up on 20000 shares in the open market at 13.40 dollars on March 9. The smart money positioned itself perfectly right before the Copenhagen presentation. Solid clinical science and strong management execution. The pipeline is delivering exactly as promised.

0 · Reply

BioSpecialOne Mar. 18 at 11:56 AM

$ARVN LETS GO

0 · Reply

Regulator06 Mar. 18 at 11:47 AM

$ARVN This will be at least 30x if they achieve first-in-class for protein degrader. As of now, they're front runner. Glta!

0 · Reply

NewGuyHere94 Mar. 12 at 8:30 PM

$ARVN insider buys, never a bad thing

0 · Reply

HedgeFollow Mar. 10 at 5:25 PM

🔍 New Buys 🔎 4th consecutive Insider Buy on $ABTC reported within 1 week. Good signal. And first on $ARVN Arvinas in a very long time. Usually they are only selling.

0 · Reply

CharlieeMungerTWITS Mar. 10 at 2:11 PM

$ARVN

1 · Reply

CharlieeMungerTWITS Mar. 9 at 2:29 PM

$ARVN slowly but surely

1 · Reply

Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson's Disease Treated for 28 Days

Mar 11, 2026, 7:00 AM EDT - 10 days ago

Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

Mar 10, 2026, 5:30 PM EDT - 11 days ago

Arvinas, Inc. (ARVN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Feb 24, 2026, 5:37 PM EST - 25 days ago

Arvinas, Inc. (ARVN) Q4 2025 Earnings Call Transcript

Feb 24, 2026, 7:00 AM EST - 25 days ago

Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Feb 23, 2026, 7:00 AM EST - 26 days ago

Arvinas to Participate in Upcoming Investor Conferences

Feb 17, 2026, 7:00 AM EST - 4 weeks ago

Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

Feb 12, 2026, 7:00 AM EST - 5 weeks ago

Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director

Dec 6, 2025, 8:05 AM EST - 3 months ago

Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition

Nov 26, 2025, 7:00 AM EST - 4 months ago

Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference

Nov 24, 2025, 7:00 AM EST - 4 months ago

Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)

Nov 5, 2025, 3:01 PM EST - 4 months ago

Arvinas, Inc. (ARVN) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 7:00 AM EST - 4 months ago

Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 3, 2025, 4:00 PM EST - 4 months ago

Arvinas to Present Preclinical Data for ARV-393 at the 2025 American Society of Hematology (ASH) Annual Meeting

Oct 29, 2025, 7:00 AM EDT - 5 months ago

Arvinas to Report Third Quarter 2025 Financial Results on November 5, 2025

Oct 24, 2025, 4:00 PM EDT - 5 months ago

Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 22, 2025, 4:00 PM EDT - 5 months ago

Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 20, 2025, 4:15 AM EDT - 5 months ago

Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy

PFE

Oct 13, 2025, 7:00 AM EDT - 5 months ago

Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Congress

Oct 5, 2025, 2:00 PM EDT - 5 months ago

Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders®

Oct 1, 2025, 7:00 AM EDT - 6 months ago

Arvinas to Present Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders®

Sep 17, 2025, 5:50 PM EDT - 6 months ago

Arvinas, Pfizer to grant commercial rights of experimental breast cancer drug to third party

PFE

Sep 17, 2025, 4:30 PM EDT - 6 months ago

Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation

Sep 9, 2025, 10:12 AM EDT - 6 months ago

Arvinas, Inc. (ARVN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Aug 8, 2025, 4:05 PM EDT - 8 months ago

Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer

Aug 6, 2025, 1:24 PM EDT - 8 months ago

Arvinas, Inc. (ARVN) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 7:00 AM EDT - 8 months ago

Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 30, 2025, 4:05 PM EDT - 8 months ago

Arvinas to Report Second Quarter 2025 Financial Results on August 6, 2025

Jul 9, 2025, 7:00 AM EDT - 9 months ago

Arvinas Announces Retirement of Chief Executive Officer and Succession Plan

Jun 13, 2025, 7:00 AM EDT - 10 months ago

Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress

Jun 6, 2025, 7:00 AM EDT - 10 months ago

Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer

Jun 5, 2025, 8:28 AM EDT - 10 months ago

Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting

May 31, 2025, 8:06 AM EDT - 10 months ago

Pfizer-Arvinas breast cancer drug tops AstraZeneca's in delaying progression

PFE

May 31, 2025, 8:00 AM EDT - 10 months ago

Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer

May 30, 2025, 7:00 AM EDT - 10 months ago

Arvinas to Present at Jefferies Global Healthcare Conference

May 16, 2025, 10:00 AM EDT - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Shareholders to Inquire about Securities Investigation

May 15, 2025, 10:00 AM EDT - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Arvinas, Inc. (ARVN) And Encourages Shareholders to Connect

May 14, 2025, 10:00 AM EDT - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arvinas, Inc. (ARVN) And Encourages Shareholders to Reach Out

May 13, 2025, 10:00 AM EDT - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Arvinas, Inc. (ARVN) and Encourages Shareholders to Learn More About the Investigation

May 12, 2025, 10:00 AM EDT - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Arvinas, Inc. (ARVN) and Encourages Investors to Learn More About the Investigation

May 11, 2025, 10:00 AM EDT - 11 months ago

Arvinas, Inc. (ARVN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Greatguns Mar. 19 at 10:49 PM

$ARVN Arvinas (NASDAQ:ARVN) Price Target Raised to $21.00 at Citigroup

0 · Reply

erevnon Mar. 19 at 1:23 PM

BTIG maintains Arvinas $ARVN at Buy and raises the price target from $14 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

BioSpecialOne Mar. 18 at 2:00 PM

2 · Reply

BioSpecialOne Mar. 18 at 12:09 PM

0 · Reply

BioSpecialOne Mar. 18 at 11:56 AM

$ARVN LETS GO

0 · Reply

Regulator06 Mar. 18 at 11:47 AM

$ARVN This will be at least 30x if they achieve first-in-class for protein degrader. As of now, they're front runner. Glta!

0 · Reply

NewGuyHere94 Mar. 12 at 8:30 PM

$ARVN insider buys, never a bad thing

0 · Reply

HedgeFollow Mar. 10 at 5:25 PM

🔍 New Buys 🔎 4th consecutive Insider Buy on $ABTC reported within 1 week. Good signal. And first on $ARVN Arvinas in a very long time. Usually they are only selling.

0 · Reply

CharlieeMungerTWITS Mar. 10 at 2:11 PM

$ARVN

1 · Reply

CharlieeMungerTWITS Mar. 9 at 2:29 PM

$ARVN slowly but surely

1 · Reply

erevnon Mar. 5 at 7:18 PM

Citigroup maintains Arvinas $ARVN at Buy and raises the price target from $15 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

CharlieeMungerTWITS Mar. 4 at 7:14 PM

$ARVN

1 · Reply

SuperGreenToday Mar. 4 at 2:28 PM

$ARVN Share Price: $13.36 Contract Selected: Oct 16, 2026 $15 Calls Buy Zone: $1.42 – $1.75 Target Zone: $2.54 – $3.10 Potential Upside: 69% ROI Time to Expiration: 225 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

CharlieeMungerTWITS Mar. 3 at 8:36 PM

$ARVN

0 · Reply

BioTechHealthX Mar. 1 at 3:19 PM

$ARVN Arvinas stock is hovering near $12 after a volatile earnings reaction, but with multiple 2026 clinical data catalysts and a cash runway into 2028, ARVN could be one of the most intriguing small-cap biotech stocks to watch. Is targeted protein degradation about to unlock major upside? https://biotechhealthx.com/biotech-news/is-arvinas-inc-arvn-a-smart-long-term-investment/

0 · Reply

BioTechHealthX Mar. 1 at 3:15 PM

$ADAP $ARVN $CING $CRVS $ETON A single FDA approval can double a small-cap biotech stock overnight. Discover 10 high-risk, high-reward FDA catalyst stocks with confirmed PDUFA dates this quarter that traders are watching for breakout moves, volatility spikes, and potential buyout speculation. https://biotechhealthx.com/biotech-news/top-10-small-cap-fda-catalyst-biotech-stocks/

1 · Reply

buyandsold Feb. 26 at 6:01 AM

$ARVN Arvinas and Pfizer plan to jointly select third party for the out-licensing and commercialization of vepdegestrant Who shall be selected for the Scarlet Letter! My guess is a newly formed entity with no commercialization track record that promises big royalties so that Noah can continue calling Vepdeg a financial asset.

0 · Reply

buyandsold Feb. 26 at 3:50 AM

$ARVN no dilution risk, also no risk to make any money. Warm to the fireside of money burning for 2.5 more years. The only way to win here is join the company and draw a salary. They even pay you after you retire.

0 · Reply

CharlieeMungerTWITS Feb. 25 at 4:56 PM

$ARVN from $10 to $13.50 is nice. We are curing breast cancer here. Let’s ride

0 · Reply

erevnon Feb. 25 at 2:46 PM

Evercore ISI Group maintains Arvinas $ARVN at Outperform and raises the price target from $14 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

erevnon Feb. 25 at 2:18 PM

Wedbush maintains Arvinas $ARVN at Neutral and raises the price target from $9 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

CharlieeMungerTWITS Feb. 24 at 9:53 PM

$ARVN

1 · Reply

Market Cap	696.54M
Revenue (ttm)	262.60M
Net Income (ttm)	-80.80M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-30.77%
Debt to Equity Ratio	0.00

Volume	2,200,600
Avg Vol	851,330
Day's Range	N/A - N/A
Shares Out	63.96M
Stochastic %K	6%
Beta	1.87
Analysts	Sell
Price Target	$14.56